Key Points
- Christine Zedelmayer, Equillium's COO, sold 100,000 shares on Dec. 23 at an average price of $1.50 for $150,000, leaving her with 91,444 shares — a 52.23% reduction in her stake.
- Zedelmayer also sold blocks on Dec. 15 (11,900 shares at $1.31), Dec. 12 (23,804 at $1.34) and Nov. 25 (8,098 at $0.95), signaling a recent pattern of insider selling while EQ trades near $1.35 and carries a consensus analyst rating of "Reduce" with an average target of $1.00.
Equillium, Inc. (NASDAQ:EQ - Get Free Report) COO Christine Zedelmayer sold 100,000 shares of the business's stock in a transaction on Tuesday, December 23rd. The shares were sold at an average price of $1.50, for a total value of $150,000.00. Following the completion of the sale, the chief operating officer directly owned 91,444 shares in the company, valued at approximately $137,166. This represents a 52.23% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.
Christine Zedelmayer also recently made the following trade(s):
- On Monday, December 15th, Christine Zedelmayer sold 11,900 shares of Equillium stock. The stock was sold at an average price of $1.31, for a total value of $15,589.00.
- On Friday, December 12th, Christine Zedelmayer sold 23,804 shares of Equillium stock. The shares were sold at an average price of $1.34, for a total value of $31,897.36.
- On Tuesday, November 25th, Christine Zedelmayer sold 8,098 shares of Equillium stock. The shares were sold at an average price of $0.95, for a total transaction of $7,693.10.
Equillium Stock Performance
EQ opened at $1.35 on Wednesday. The firm has a market cap of $82.20 million, a price-to-earnings ratio of -2.18 and a beta of 1.92. The firm's 50-day simple moving average is $1.15 and its 200-day simple moving average is $1.03. Equillium, Inc. has a twelve month low of $0.27 and a twelve month high of $2.35.
Equillium (NASDAQ:EQ - Get Free Report) last announced its quarterly earnings results on Thursday, November 13th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.08. As a group, sell-side analysts anticipate that Equillium, Inc. will post 0.14 EPS for the current fiscal year.
Wall Street Analyst Weigh In
EQ has been the topic of a number of research analyst reports. Wall Street Zen upgraded Equillium from a "sell" rating to a "hold" rating in a research report on Saturday, November 15th. Weiss Ratings reissued a "sell (d-)" rating on shares of Equillium in a research note on Monday. Two investment analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Reduce" and an average target price of $1.00.
Read Our Latest Stock Analysis on EQ
Institutional Trading of Equillium
Hedge funds and other institutional investors have recently modified their holdings of the stock. Hudson Bay Capital Management LP bought a new position in Equillium in the 3rd quarter worth approximately $398,000. Cantor Fitzgerald L. P. acquired a new stake in shares of Equillium in the 3rd quarter valued at $608,000. Woodline Partners LP bought a new stake in shares of Equillium during the third quarter worth $5,018,000. Millennium Management LLC bought a new stake in shares of Equillium during the third quarter worth $35,000. Finally, Boothbay Fund Management LLC acquired a new position in shares of Equillium during the third quarter valued at $174,000. Institutional investors and hedge funds own 27.05% of the company's stock.
About Equillium
(
Get Free Report)
Equillium, Inc (NASDAQ: EQ) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies to treat severe autoimmune diseases and prevent organ transplant rejection. The company's lead therapeutic candidate, EQ001 (itolizumab), is a humanized monoclonal antibody that modulates T-cell activation by targeting the CD6 receptor. Equillium's pipeline also includes additional biologic candidates aimed at addressing indications such as acute graft-versus-host disease (GVHD) and lupus nephritis.
Founded in 2015 and headquartered in La Jolla, California, Equillium in-licensed itolizumab from Biocon Limited, leveraging the antibody's established safety profile in earlier clinical studies.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
